Product: TGFR™ System

Company: MediBeacon Inc.

About the Product:

For the millions of people who manage diabetes with multiple daily injections, every meal brings another series of decisions: calculating insulin, remembering doses, and balancing blood sugar throughout the day. MiniMed Go was designed to reduce that daily mental burden. By bringing smart insulin pen data, continuous glucose monitoring, personalized dosing guidance, and real-time alerts into one app, it transforms disconnected sources of information into timely action. Rather than simply displaying data, MiniMed Go helps people make more confident treatment decisions, simplifying diabetes management while improving adherence and supporting better outcomes.

Product: AeroPace®

Company: Lungpacer Medical

About the Product:

Lungpacer's AeroPace System is the first and only transvenous diaphragm neurostimulation system for patients struggling to breathe independently and wean from mechanical ventilation. Every day on a ventilator weakens the diaphragm, trapping patients in a cycle of unnecessary mechanical ventilation. AeroPace breaks that cycle by stimulating the phrenic nerves to activate and strengthen the diaphragm while patients are still ventilated, helping them breathe on their own sooner. In the pivotal RESCUE-3 trial, patients weaned 43% faster and spent 3.2 fewer days on ventilation. Lungpacer's mission is simple: liberate patients from the vent and give them the freedom to breathe again.

Product: Exablate® Neuro

Company: Insightec

About the Product:

Exablate® Neuro, developed by Insightec, is the first MR-guided focused ultrasound platform FDA-approved to treat advanced symptoms of Parkinson's disease, including debilitating tremor, rigidity, mobility impairment, and medication-induced dyskinesia. Using submillimeter-accurate lesioning guided by real-time MRI and thermal mapping, physicians perform incisionless brain surgery on deep brain structures, without opening the skull or implanting hardware. This approach gives patients whose symptoms persist despite optimized medication a meaningful treatment option, delivered through an intact skull with no incisions, electrodes, or ongoing device management required. Supported by randomized controlled trials and multicenter studies, Exablate Neuro represents a new paradigm in functional neurosurgery.

Product: LumiSystem™

Company: Lumicell

About the Product:

LumiSystem is the combination of two FDA approved products: LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS). LUMISIGHT is an optical imaging agent that fluoresces at sites of suspected cancerous tissue. Lumicell DVS is an imaging device that provides fluorescence guidance. This combination is used intraoperatively to illuminate breast cancer, in real-time, within the resection cavity following the removal of cancer in a lumpectomy surgery, enhancing the standard of care. Not for promotional use. Visit www.lumisystem.com for full Product Information, including Boxed Warning.

Product: LungFit® PH

Company: Beyond Air, Inc.

About the Product:

Beyond Air is a medical technology company advancing nitric oxide therapy through innovative, accessible solutions. Recognizing the need for a simpler, more sustainable approach to inhaled nitric oxide (iNO) delivery, Beyond Air developed LungFit® PH, an FDA-approved and CE-Marked, tankless system that generates nitric oxide from ambient air. By eliminating compressed gas cylinders and chemicals, LungFit PH reduces the logistical burden, waste, and complexity associated with traditional iNO delivery. This breakthrough technology is designed to simplify treatment delivery and hospital operations while helping healthcare teams focus resources where they matter most: delivering high-quality care to vulnerable patients.

Product: TRAUMAGEL®

Company: Cresilon

About the Product:

TRAUMAGEL® is a revolutionary plant-based hemostatic gel that controls bleeding in seconds. The groundbreaking medical technology from Brooklyn-based Cresilon is designed to stop bleeding rapidly, provide immediate hemorrhage control, and save lives. TRAUMAGEL is the first-ever gel in a syringe for traumatic hemorrhage and the only flowable hemostatic device with FDA clearance for temporary external use to control moderate to severe bleeding. Since its nationwide launch in January 2025, TRAUMAGEL’s clinical use has continued growing with licensed medical professionals applying it to a wide variety of moderate to severe bleeds, including gunshot wounds, equipment injuries, head lacerations, and tourniquet conversions.

Product: UNITY® Vitreoretinal Cataract System (VCS)

Company: Alcon

About the Product:

UNITY® Vitreoretinal Cataract System (VCS) is developed by Alcon, the global leader in eye care. UNITY VCS is designed to meet the evolving demands of cataract and vitreoretinal surgery, incorporating more than a dozen innovations into a single advanced platform. By integrating multiple technologies and functions, it simplifies operating room workflows, reduces complexity, and aims to help surgeons work efficiently without compromising quality. With built-in safety features and enhanced workflow efficiency, UNITY VCS supports the delivery of high-quality care to more patients worldwide.
Discovered and developed entirely by CSL, ANDEMBRY® fuses leading scientific experience with deep patient insights plus state-of-the-art formulation and device development, all leading to a once-monthly, small-volume dose delivered via a convenient autoinjector. It is remarkably well tolerated, safe, and leads to strong, durable efficacy. This combination of features marks a significant advance in HAE care and allows patients to lead fuller lives. It also demonstrates the power of CSL’s scientific persistence, its focus on enduring patient impact, and its willingness to disrupt itself in the service of bettering patients’ lives.

Product: Shockwave C2 Coronary IVL Catheter

Company: Johnson & Johnson

About the Product:

Shockwave C2 IVL Catheter The Shockwave™ C2 Intravascular Lithotripsy (IVL) Catheter uses ultrasonic acoustic pressure waves to fracture calcium in hardened arteries. The technology represents a paradigm shift in calcified coronary artery disease (CAD) treatment with a new mechanism of action to address one of cardiology's most persistent challenges. It allows physicians to treat deep and superficial calcium safely and effectively, without damaging the soft tissue of the vessel wall or creating clinically meaningful embolic debris — something no prior technology has achieved. Shockwave C2 offers a safer, more effective and predictable solution for patients with complex CAD.